What does Invion Limited do?

Invion Limited (IVIXF) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is IVIXF's market cap?

Invion Limited (IVIXF) has a market capitalization of approximately $4.0 million, as of August 25, 2026, based on the most recent share price and shares outstanding.

Does IVIXF pay a dividend?

No — Invion Limited (IVIXF) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Invion Limited (IVIXF) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

IVIXF

Invion Limited

OTC·Drug Manufacturers, Specialty & Generic · Healthcare

$0.04$0.00+0.00%

Market cap$4.03M·Market closed·Aug 25 8:00 PM UTC

Price Chart

$0.04+$0.00 (+0.00%)today

−95.99%CAGR −47.45%

Select date range

FromTo

May 17, 2013Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

IVIXF does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateFeb 26

Last Report DateFeb 26

Reported vs Estimate−$0.03

Earnings Surprise—

FinancialsFinancials Tab

Revenue$0.00

Net Income−$5.86M

Net Margin—

Operating Cash Flow−$1.71M

Capital Expenditures$0.00

Free Cash Flow−$1.71M

Return on Equity−153.9%

Return on Invested Capital−55.0%

Net Debt$327.04K

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for IVIXF and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how IVIXF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IVIXF and 80,000+ other tickers.

About Invion Limited

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts. It holds an R&D agreement with the Hudson Institute of Medical Research, partnering…

CEO: Thian Chew
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: OTC
Employees: 4
Website: www.inviongroup.com

Peers

Aoxing Pharmaceutical Company, Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About IVIXF

What does Invion Limited do?: Invion Limited (IVIXF) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is IVIXF's market cap?: Invion Limited (IVIXF) has a market capitalization of approximately $4.0 million, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does IVIXF pay a dividend?: No — Invion Limited (IVIXF) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is IVIXF profitable?: Invion Limited (IVIXF) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.